stockrow
Friday 6 November 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
86.43
3.42
+4.12%
Follow DNTH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 2 |
+8 more TTM periods Free account |
| (22.61%) | (26.07%) | (22.70%) | (38.38%) | ||
| (21.81%) | (24.98%) | (21.77%) | (35.88%) | ||
ROIC |
(36.55%) | (47.74%) | (132.76%) | (124.80%) | |
Return on Tangible Assets |
(24.40%) | (22.26%) | (16.05%) | (42.83%) | |
Average Days of Receivables |
78.16 | 20.32 | 336.04 | 9.32 | |
Free Cash Flow per Share |
(3.07) | (2.78) | (2.72) | (3.35) | |
Free Cash Flow |
(175.85) | (155.71) | (130.48) | (129.27) | |
Capital Expenditures |
(0.70) | (0.33) | (0.20) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(8.46%) | (7.56%) | (5.64%) | (14.40%) | |
Accounts Receivable Turnover |
0.97 | 26.26 | 1.20 | 4.74 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,942.94% | 9,222.58% | 11,464.30% | 7,153.14% | |
Selling, General and Administrative Expense of Revenue |
1,840.95% | 2,318.80% | 2,953.74% | 1,686.20% | |
Share Based Compensation of Revenue |
1,515.78% | 1,800.00% | 2,101.80% | 1,119.50% | |
Operating CF/Net income |
0.87 | 0.81 | 0.75 | 0.80 | |
Depreciation/Fixed assets |
(10.97) | (23.11) | (18.65) | (19.37) | |
Capex/Depreciation |
0.08 | 0.03 | 0.04 | 0.04 | |
Revenue per Share |
0.05 | 0.03 | 0.03 | 0.05 | |
Operating CF per Share |
(3.05) | (2.77) | (2.71) | (3.34) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.26 | 0.18 | 0.15 | 0.10 |
Columns are period end dates · fundamentals updated 6 Nov 2026